Valproate, also known as valproate sodium or valproic acid, is approved in various forms to treat seizures, bipolar disorder, and migraine headaches. In combination with levocarnitine, it was being tested in a Phase 3 clinical trial as an oral medication to improve motor function in people with spinal muscular atrophy (SMA), but the status of that study, due to conclude in 2016, is not known.
Clinical trial news
Last updated Nov. 15, 2022, by Marisa Wexler, MS Fact-checked by Ana de Barros, PhD What is reldesemtiv for SMA? Reldesemtiv (formerly CK-2127107) is an investigational oral therapy designed to increase muscle strength that Cytokinetics is developing as a potential treatment for spinal muscular atrophy (SMA). As…
Should results of a Phase 3 trial of apitegromab, a muscle-directed therapy for spinal muscular atrophy, be positive when released later this year as expected — supporting the add-on therapy being approved — apitegromab could be available to U.S. patients in 2025, Scholar Rock, its developer, announced.
Three years of treatment with apitegromab, a muscle-targeting therapy being developed by Scholar Rock, continues to provide clinical benefit to children and young adults with spinal muscular atrophy (SMA) type 2 or 3 who are not able to walk. That’s according to long-term results from the open-label…
More than 90% of children with spinal muscular atrophy (SMA) type 1 who started taking Evrysdi (risdiplam) as babies are still alive and achieving motor milestones that would be unattainable without treatment, according to final, five-year data from the FIREFISH clinical trial. The findings were presented at the…
